Center for Lymphoma, Massachusetts General Hospital Cancer Center
Oncology
Dr. Jeremy S. Abramson, MD
|
|
Give Review
Jeremy Abramson is an expert in the field of Oncology. He studied medicine at Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai is ranked 20/62 in Research/PrimaryCare. He received awards:"Most Compassionate Doctor". Jeremy Abramson is a published doctor as well. He has 30 publications published. The latest was: Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. He is registered with Medicare and accepts Medicare payments.
Publications
- Routine conventional karyotyping of Lymphoma staging bone marrow samples does not contribute clinically relevant information.
- Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for Lymphoma.
- Diagnosis and management of castleman Disease.
- Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin Lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbaz...
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit Lymphoma: a multicenter retrospective analysis.
- Extranodal Marginal Zone Lymphoma Presenting As Miliary Lung Disease.
- Posterior Reversible Encephalopathy Syndrome (PRES) Complicating Newly-Diagnosed Diffuse Large B-Cell Lymphoma.
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin Lymphoma.
- Treatment of primary mediastinal B-cell Lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary re...
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell Lymphoma.
- Oral clofarabine for relapsed/refractory non-Hodgkin Lymphomas: results of a phase 1 study.
- Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU, and etoposide (CBV) followed by autologous stem Cell transplant.
- Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (tbc) conditioning in patients with cns involvement by non-hodgkin Lymphoma.
- Non-Hodgkin's Lymphomas.
- Intravenous methotrexate as central Nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell ly...
- Case records of the Massachusetts General Hospital. Case 24-2010. A 56-year-old woman with a history of Hodgkin's Lymphoma and sudden onset of dyspnea and shock.
- Treatment of favorable, limited-stage Hodgkin's Lymphoma with chemotherapy without consolidation by radiation therapy.
- NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's Lymphomas.
- B-cell Lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt Lymphoma and diff...
- Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic Leukemia.
- Adult T-cell Leukemia/lymphoma: complexities in diagnosis and novel treatment strategies.
- Case records of the Massachusetts General Hospital. Case 27-2009. A 56-year-old woman with fever, rash, and lymphadenopathy.
- Evaluating the impact of the humanities in medical education.
- The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell Lymphomas.
- Case records of the Massachusetts General Hospital. Case 39-2008. A 51-year-old woman with splenomegaly and Anemia.
- Case records of the Massachusetts General Hospital. Case 8-2008. A 33-year-old man with fever, abdominal pain, and pancytopenia after renal transplantation.
- Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
- T-cell/histiocyte-rich B-cell Lymphoma: biology, diagnosis, and management.
- Advances in the biology and therapy of diffuse large B-cell Lymphoma: moving toward a molecularly targeted approach.
Schools
Mount Sinai School of Medicine
Massachusetts General Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Most Compassionate Doctor
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Icahn School of Medicine at Mount Sinai
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1740262484 | |
| NPPES Provider LastName | ABRAMSON | |
| NPPES Provider FirstName | JEREMY | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology | |
| Total Claim Count | 113.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740262484 |
| Last Name Of The Provider | ABRAMSON |
| First Name Of The Provider | JEREMY |
| View All |
Similar Doctors
|
|
Dr. Steven L. McAfee, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Katayoon Goodarzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judson M. Englert, MD |
|
|
Dr. Benjamin J. Drapkin, MD |
|
|
Dr. Pavan Bachireddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Russell W. Jenkins, MD |
|
|
Dr. Rinath M. Jeselsohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph P. Eder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aleksandra A. McLeod, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer L. Westrup, MD
This Doctor is OpenDoctor Recommended.
|